Mark Pulse

949 total citations
30 papers, 512 citations indexed

About

Mark Pulse is a scholar working on Infectious Diseases, Epidemiology and Molecular Medicine. According to data from OpenAlex, Mark Pulse has authored 30 papers receiving a total of 512 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Infectious Diseases, 15 papers in Epidemiology and 6 papers in Molecular Medicine. Recurrent topics in Mark Pulse's work include Clostridium difficile and Clostridium perfringens research (14 papers), Microscopic Colitis (10 papers) and Antibiotic Resistance in Bacteria (6 papers). Mark Pulse is often cited by papers focused on Clostridium difficile and Clostridium perfringens research (14 papers), Microscopic Colitis (10 papers) and Antibiotic Resistance in Bacteria (6 papers). Mark Pulse collaborates with scholars based in United States, France and India. Mark Pulse's co-authors include Jason Weiss, Jerry W. Simecka, Kristine M. Hujer, Andrea Endimiani, Andrea M. Hujer, Robert A. Bonomo, Richard Vickers, Jae H. Park, Martin Handfield and Johan A. Kers and has published in prestigious journals such as The Journal of Immunology, PLoS ONE and Scientific Reports.

In The Last Decade

Mark Pulse

29 papers receiving 497 citations

Peers

Countries citing papers authored by Mark Pulse

Since Specialization

Citations

This map shows the geographic impact of Mark Pulse's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Pulse with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Pulse more than expected).

Fields of papers citing papers by Mark Pulse

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Pulse. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Pulse. The network helps show where Mark Pulse may publish in the future.

Co-authorship network of co-authors of Mark Pulse

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Pulse. A scholar is included among the top collaborators of Mark Pulse based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Pulse. Mark Pulse is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Suppression of host humoral immunity by Borrelia burgdorferi varies over the course of infection 2024 ·Infection and Immunity ·(unknown), Yan Zhang, Mark Pulse, Rance E. Berg, Michael S. Allen	0
2	Nasal Tumor Vaccination Protects against Lung Tumor Development by Induction of Resident Effector and Memory Anti-Tumor Immune Responses 2023 ·Pharmaceutics ·(unknown), (unknown), (unknown), (unknown), Mark Pulse, Amalendu P. Ranjan, Pankaj Chaudhary, Harlan P. Jones	10
3	Design, Synthesis, and Characterization of TNP-2198, a Dual-Targeted Rifamycin-Nitroimidazole Conjugate with Potent Activity against Microaerophilic and Anaerobic Bacterial Pathogens 2022 ·Journal of Medicinal Chemistry ·Zhenkun Ma, (unknown), Ying Yuan, (unknown), Yu Liu, Huan Wang, Jing Chen, (unknown), Charles Z. Ding, Vadim Molodtsov, Wei Lin, Gregory T. Robertson, Jason Weiss, Mark Pulse, Phung M. Nguyen, Leonard R Duncan, Timothy B Doyle, Richard H. Ebright, A. Simon Lynch	18
4	Discovery of VNRX-7145 (VNRX-5236 Etzadroxil): An Orally Bioavailable β-Lactamase Inhibitor for Enterobacterales Expressing Ambler Class A, C, and D Enzymes 2021 ·Journal of Medicinal Chemistry ·Robert E. Lee Trout, Allison L. Zulli, Eugen F. Mesaros, Randy W. Jackson, Steven A. Boyd, Bin Liu, (unknown), Denis M. Daigle, (unknown), (unknown), (unknown), (unknown), Jason Weiss, Mark Pulse, Daniel C. Pevear, Greg Moeck, L Xerri, Christopher J. Burns	30
5	Oral Immunotherapy With Human Secretory Immunoglobulin A Improves Survival in the Hamster Model of Clostridioides difficile Infection 2021 ·The Journal of Infectious Diseases ·Estelle Chiari, Jason Weiss, Michael R. Simon, S.T. Kießig, Mark Pulse, Stephen Brown, (unknown), (unknown), (unknown), Christoph von Eichel‐Streiber	7
6	Epidemic ribotypes of Clostridium (now Clostridioides) difficile are likely to be more virulent than non-epidemic ribotypes in animal models 2020 ·BMC Microbiology ·(unknown), Mark Pulse, (unknown), Jerry W. Simecka	9
7	Novel Chitohexaose Analog Protects Young and Aged mice from CLP Induced Polymicrobial Sepsis 2019 ·Scientific Reports ·Pragnya Das, Sujogya Kumar Panda, Beamon Agarwal, Sumita Behera, Mansoor Ali Syed, Mark Pulse, Joseph S. Solomkin, Steven M. Opal, Vineet Bhandari, (unknown)	24
8	Primary care clinics can be a source of exposure to virulent Clostridium (now Clostridioides) difficile: An environmental screening study of hospitals and clinics in Dallas-Fort Worth region 2019 ·PLoS ONE ·Jerry W. Simecka, Kimberly G. Fulda, Mark Pulse, (unknown), (unknown), Phung M. Nguyen, Patricia E. Taylor, (unknown), (unknown), Sushma Sharma	4
9	In Vivo Efficacy of Novel Monobactam LYS228 in Murine Models of Carbapenemase-Producing Klebsiella pneumoniae Infection 2019 ·Antimicrobial Agents and Chemotherapy ·Jason Weiss, Mark Pulse, Phung M. Nguyen, Ellena Growcott	5
10	Antibiotic-Induced Dysbiosis Predicts Mortality in an Animal Model of Clostridium difficile Infection 2018 ·Antimicrobial Agents and Chemotherapy ·Charles Burdet, (unknown), Thu Thuy Nguyen, Perrine Hugon, (unknown), (unknown), Tanguy Corbel, Stéphanie Ferreira, Mark Pulse, Jason Weiss, Antoine Andremont, France Mentré, Jean de Gunzburg	21
11	Mutacin 1140 Lantibiotic Variants Are Efficacious Against Clostridium difficile Infection 2018 ·Frontiers in Microbiology ·Johan A. Kers, Robert E. Sharp, (unknown), Jae H. Park, Jin Xu, Mark Pulse, Jason Weiss, Martin Handfield	37
12	OG716: Designing a fit-for-purpose lantibiotic for the treatment of Clostridium difficile infections 2018 ·PLoS ONE ·Johan A. Kers, (unknown), Jae H. Park, Jin Xu, Mark Pulse, Jason Weiss, Martin Handfield	17
13	Activity of Meropenem-Vaborbactam against Carbapenem-Resistant Enterobacteriaceae in a Murine Model of Pyelonephritis 2017 ·Antimicrobial Agents and Chemotherapy ·Jason Weiss, Mark Pulse, Phung M. Nguyen, (unknown), Jessica Silva-Fisher, Jerry W. Simecka, (unknown), Mojgan Sabet, David C. Griffith	16
14	In Vivo Assessment of SMT19969 in a Hamster Model of Clostridium difficile Infection 2014 ·Antimicrobial Agents and Chemotherapy ·Jason Weiss, Mark Pulse, Richard Vickers	30
15	DAV131, AN ORAL ADSORBENT-BASED PRODUCT, FULLY PROTECTS HAMSTERS AGAINST MOXIFLOXACIN-INDUCED CLOSTRIDIUM DIFFICILE LETHAL INFECTION 2012 ·Christine Miossec, (unknown), Élisabeth Chachaty, Jason Weiss, Mark Pulse, (unknown), Antoine Andremont, Jean de Gunzburg	1
16	Small Molecule Inhibitors of Staphylococcus aureus RnpA Alter Cellular mRNA Turnover, Exhibit Antimicrobial Activity, and Attenuate Pathogenesis 2011 ·PLoS Pathogens ·Patrick D. Olson, Lisa Kuechenmeister, Kelsi L. Anderson, (unknown), Karen E. Beenken, Christelle M. Roux, Michelle L. Reniere, (unknown), Jason Weiss, Mark Pulse, Phung M. Nguyen, Jerry W. Simecka, John M. Morrison, Khalid Sayood, Oluwatoyin A. Asojo, Mark S. Smeltzer, Eric P. Skaar, Paul M. Dunman	52
17	Corticotropin-releasing hormone receptor-1 and 2 activity produces divergent resistance against stress-induced pulmonary Streptococcus pneumoniae infection 2011 ·Journal of Neuroimmunology ·Byung Jin Kim, (unknown), Jerry W. Simecka, Mark Pulse, Harlan P. Jones	11
18	Stress-induced differences in primary and secondary resistance against bacterial sepsis corresponds with diverse corticotropin releasing hormone receptor expression by pulmonary CD11c+ MHC II+ and CD11c− MHC II+ APCs 2008 ·Brain Behavior and Immunity ·(unknown), (unknown), Mark Pulse, (unknown), Harlan P. Jones	18
19	Simultaneous determination of rifampicin and levofloxacin concentrations in catheter segments from a mouse model of a device-related infection by liquid chromatography/electrospray ionization tandem mass spectrometry 2007 ·Journal of Pharmaceutical and Biomedical Analysis ·Donghui Bao, (unknown), Paul J. Renick, Mark Pulse, Jason Weiss	19
20	Synthesis and antibacterial evaluation of a novel series of rifabutin-like spirorifamycins 2006 ·Bioorganic & Medicinal Chemistry Letters ·In Ho Kim, Keith D. Combrink, Zhenkun Ma, (unknown), Dalai Yan, Paul J. Renick, Timothy W. Morris, Mark Pulse, Jerry W. Simecka, Charles Z. Ding	12

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact